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IntroductIon
CD177 is a neutrophil-specific receptor with clinical signif-
icance in allo- and autoimmune diseases (Stroncek, 2007). 
CD177 harbors the human neutrophil antigen 2 (HNA-2; 
formerly neutrophil antigen B1 or NB1). Alloantibodies to 
HNA-2, either actively generated or acquired from blood 
products, can cause severe neutropenia in newborns (Lalezari 
et al., 1971), graft failure in bone marrow recipients (Stron-
cek et al., 1993), drug-induced neutropenia (Stroncek et al., 
1994), and transfusion-related lung injury (TRA LI; Bux et 
al., 1996; Sachs et al., 2006). In addition, CD177 presents pro-
teinase 3 (PR3), a major autoantigen in antineutrophil cyto-
plasmic antibodies (ANCA)-associated small vessel vasculitis 
on the neutrophil surface (Bauer et al., 2007; von Vietinghoff 
et al., 2007). PR3-ANCA bind to membrane-exposed PR3 
(mPR3) and activate the neutrophil—a central process for 
subsequent vascular injury (Kettritz, 2012). Above and beyond 
its role in immune conditions, CD177 facilitates neutrophil 
endothelial transmigration involving heterophilic PEC AM-1 
interactions and catalytic membrane PR3 activity (Sachs et 
al., 2007; Bayat et al., 2010; Kuckleburg et al., 2012).
CD177 is a glycosyl-phosphatidyl inositol–linked gly-
coprotein of the urokinase plasminogen activator receptor/
CD59/Ly6 snake toxin superfamily (Kissel et al., 2001). 
CD177 protein is stored in secondary granules and is pre-
sented on the neutrophil plasma membrane (von Vietinghoff 
et al., 2008; Rørvig et al., 2013). CD177 shows a peculiar dis-
tribution pattern in that ∼95% of all healthy individuals pro-
duce CD177pos neutrophils, whereas 5% are CD177 deficient 
(Goldschmeding et al., 1992; Matsuo et al., 2000; Li et al., 
2015; Wu et al., 2016). However, even the CD177-producing 
individuals show a stable bimodal CD177 pattern over time, 
with distinct membrane CD177neg and CD177pos (mCD177) 
neutrophil subsets. The size of the latter ranges from a few, 
to >90% (Goldschmeding et al., 1992). Despite the strong 
clinical implications, the mechanisms controlling sub-
set-restricted CD177 gene expression in bimodal individuals 
are incompletely understood.
Most diploid cells express both parental alleles of each 
gene, whereas some genes are monoallelically expressed. To 
date, two basic monoallelic expression (MAE) mechanisms 
in autosomes are distinguished. Imprinting describes a par-
ent-of-origin MAE with exclusive silencing of either the ma-
ternal or the paternal allele (Barlow and Bartolomei, 2014). In 
contrast, classical random MAE occurs stochastically, so that 
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clonal cells derived from a given cell type express either the 
maternal or the paternal, or even both parental alleles (Gimel-
brant et al., 2007; Deng et al., 2014).
We CD177-phenotyped a large cohort of healthy indi-
viduals and studied genetic and epigenetic mechanisms that 
control CD177 expression using sorted neutrophil CD177 
subsets, parent-offspring trios, neutrophil-differentiated 
CD34+ hematopoietic stem cells (HSCs), neonatal cord 
blood neutrophils, and a HeLa cell model. We demonstrate 
that disparate CpG and histone methylation, and AP-1 
(c-Jun/c-Fos) transcription factor (TF) binding explain the 
two distinct CD177 neutrophil subsets. We observed MAE 
of CD177 with a novel pattern that follows neither classical 
random MAE nor imprinting.
resuLts
neutrophil mcd177 phenotypes in normal controls
We first characterized the CD177 neutrophil phenotype in 
165 normal individuals (66 men and 99 women). We assessed 
mCD177 on viable blood neutrophils by flow cytometry and 
found that 6% (10/165) of the individuals were completely 
CD177 deficient. In contrast, 94% (155/165) showed a bi-
modal pattern with varying percentages of mCD177pos neu-
trophils. The median size of the mCD177pos subset was 60% 
(Fig. 1 A). Our subsequent studies focused on the molecular 
basis for the CD177 bimodality that involves the vast majority 
of healthy individuals and has major disease implications for 
allo- and autoantigen presentation.
cd177 protein and mrnA expression is restricted to the 
cd177pos neutrophil subset
To gain insight into the molecular basis of the two dis-
tinct mCD177 phenotypes, we analyzed CD177 protein 
and mRNA expression in bimodal mCD177 individuals. 
For these studies, we isolated highly pure CD177neg and 
CD177pos blood neutrophils by magnetic cell sorting 
(Fig. 1 B). Immunoblotting showed CD177 protein (Fig. 1 C) 
and qRT-PCR detected full-length mRNA (Fig.  1  D) in 
CD177pos, but not in CD177neg neutrophils. To precisely check 
CD177 transcription in CD177neg neutrophils, we used three 
different primer pairs to exclude truncated CD177 mRNAs 
by qRT-PCR (Fig. 1 E). Thus, CD177 full-length mRNA is 
actively transcribed in CD177pos neutrophils, whereas both 
mRNA and protein are absent in the CD177neg subset.
cd177 is monoallelically expressed in neutrophils and 
neutrophil-differentiated cd34+ Hscs
The human CD177 gene resides on chromosome 19q13.31, 
8.4-kb downstream to a CD177 pseudogene (Bettinotti et 
al., 2002; Caruccio et al., 2006; Li et al., 2015). We next in-
vestigated the CD177 gene locus to determine whether or 
not structural aberrations, such as frame shifts, deletions, or 
alternative splice sites explained the lack of CD177 mRNA 
in CD177neg neutrophils. We sequenced the CD177 gene 
in the two separated CD177 subsets (mCD177neg and 
mCD177pos neutrophils) and detected no DNA mutations or 
major substitutions in the nine exons, exon–intron transitions, 
5′ UTR (−1,000 bp), and in 3′ UTR (+200 bp). In addition, 
a genome-wide single nucleotide polymorphisms (SNPs) 
analysis using an Affimetrix SNP array 6.0, revealed an almost 
identical SNP and copy number variation (CNV) concor-
dance in both neutrophil subsets (five biological replicates, 
99.9% concordance by Fisher’s exact test; Fig. S1).
Because no CD177 DNA sequence alterations or CNVs 
were found to explain the distinct CD177 mRNA and pro-
tein patterns, we performed a systematic haplotype analysis for 
the CD177 locus with 17 trios from 12 healthy families. We 
first sequenced the CD177 exons from parents and offspring. 
Long-range PCR was used to amplify the complete CD177 
gene, thereby excluding the highly homologous pseudogene 
(exons 4–9) in reverse orientation on the antisense strand. 
Sequencing and SNP analysis of the PCR-amplicon (13 kb) 
detected all 9 CD177 exons confirming that the product was 
not contaminated by the CD177 pseudogene. Within the 
CD177 exons, we found 22 heterozygous SNPs in 15/17 
offspring (Table S1) ranging from 1 to 6 in a given child. The 
remaining two offspring had noninformative homozygous 
SNPs. Only heterozygous SNPs analyzed in DNA and corre-
sponding mRNA from neutrophils enabled us to distinguish 
the two parental CD177 alleles and to determine whether or 
not both alleles were actively transcribed. To our surprise, we 
found MAE in all 15 offspring with heterozygous SNPs. The 
parental origin of the actively transcribed allele was identified 
in 12/15 children, whereas three offspring had no informative 
SNP. 3/5 daughters expressed the maternal and 2/5 the pa-
ternal CD177 allele, whereas 5/7 sons expressed the maternal 
and 2/7 the paternal allele. These data indicate that the paren-
tal choice occurred independently of the offspring’s gender. 
Remarkably, siblings from two of the 12 families inherited 
the expressed CD177 allele from a different parent (Fig. 1 F 
and S2 A). One of these two families allowed sibling testing 
that confirmed the full-sibling status (Fig. S2 A). We comple-
mented Sanger sequencing in the family shown in Fig. 1 F, 
with more quantitative approaches, namely digital PCR with 
informative SNP-specific probes and pyrosequencing, respec-
tively. Results from both assays were >70% cut-off used for a 
monoallelic call (Reinius and Sandberg, 2015) and strengthen 
the observation of monoallelic CD177 expression (Fig. 1, G 
and H). The haplotypes of all remaining trios are shown in 
Fig. S1 B. We then studied MAE in a given individual over 
a 7-d period at days 0, 3, and 7, respectively. We observed 
that the allelic choice was stable and did not change over 
the observation period (Table 1). Together, these data indi-
cate monoallelic CD177 expression in CD177pos neutrophils. 
The expressed CD177 transcript in a given individual was 
derived randomly either from the maternal or paternal allele 
with variation even within one family and the allelic choice 
remained stable over time.
To elucidate the mechanism of CD177 MAE, we stud-
ied CD34+ hematopoietic stem cell (HSC)–derived neu-
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trophils and neonatal neutrophils of the identical donor. We 
questioned whether or not CD177 MAE was already deter-
mined in the pluripotent HSCs. Thus, we selected umbili-
cal cord blood donors with heterozygous DNA SNPs that 
allowed us to determine whether or not both alleles were 
expressed in the CD177 mRNA transcripts. G-CSF induced 
neutrophil differentiation and the HSC-derived neutrophils 
expectantly expressed the maturation markers CD11b and 
CD18 on the surface, showed bimodal CD177 populations 
(Fig. 2 A), and progressively transcribed CD177 mRNA over 
the 7-d observation period (Fig. 2 B). Analyzing heterozy-
gous SNPs in CD177 DNA and mRNA by sequencing, we 
Figure 1. cd177pos neutrophils from bimodal in-
dividuals contain cd177 protein and express only 
one cd177 allele either of paternal or maternal 
origin, whereas cd177neg neutrophils produce 
neither cd177 protein nor mrnA. (A) The percent-
age of CD177pos neutrophils by flow cytometry in 165 
normal controls is shown as percentage of individuals 
per decile. (B) A typical flow cytometry experiment be-
fore (presort) and after magnetic cell sorting yielding 
CD177pos and CD177neg neutrophil subsets is given. 
Samples obtained as shown in B were subjected (C) to 
immunoblotting for CD177 and proteinase 3 (PR3) as 
a control protein (n = 4 different donors), and (D) to 
CD177 gene expression analysis by qRT-PCR. CD177 
mRNA of presorted neutrophils was set at 100% (n = 
3 different donors). (E) RT-PCR with different CD177 
exon-spanning primers (black arrows) was performed 
in CD177pos and CD177neg neutrophils from two neu-
trophil donors to exclude truncated CD177 mRNAs (n 
= 2 different donors). (F) An example for monoallelic 
CD177 gene expression in a family with two offspring 
is depicted. Haplotype analysis showed an informa-
tive heterozygous GA SNP (in red, rs45571738) in the 
genomic DNA (gDNA) of both offspring whereas ma-
ternal gDNA showed homozygous GG and paternal 
gDNA AA. At mRNA, the son monoallelically expressed 
the maternal G and the daughter the paternal A allele 
as demonstrated by Sanger sequencing. The parental 
haplotype that is inherited by the offspring is boxed in 
light orange (maternal) and blue (paternal). (G) Digi-
tal PCR for the monoallelically expressed G allele for 
SNP156 in the son (left) and A allele in the daughter 
(right). Dot plots are depicted with each dot represent-
ing one of the 20,000 analyzed wells on the digital 
PCR chip. Blue dots represent the G (FAM-labeled) and 
red dots the A (VIC-labeled) allele, whereas yellow and 
green dots do not allow unequivocal allele identifica-
tion. Quantitative assessment (middle) shows 75% G 
allele expression for the son and 96% for the daugh-
ter. gDNA was assessed as a control showing even 
distribution of both alleles (n = 2). (H) Pyrosequenc-
ing reveals MAE of the G allele (74%) for the son and 
the A allele (72%) for the daughter, respectively. Note 
that quantitative assays for assessment of MAE use a 
threshold of ∼70% for the monallelic call (Reinius and 
Sandberg, 2015). Data in D were displayed as mean± 
SEM and were analyzed using one-way ANO VA. ***, P 
< 0.001. Data in G were given as Poisson plus ratio 
with confidence intervals and were analyzed using 
Student’s t test. **, P < 0.01.
CD177 genetics | Eulenberg-Gustavus et al.2092
found that both CD177 alleles were transcribed in undiffer-
entiated CD34+ HSCs. However, biallelic CD177 expres-
sion changed to MAE with neutrophil differentiation at day 
7 (Fig.  2 C). When we compared neutrophil-differentiated 
HSCs with the mature neonatal neutrophils obtained from 
the same cord blood, we validated MAE and found that the 
identical CD177 allele was monoallelically transcribed in in 
vitro G-CSF differentiated and in in vivo natively differenti-
ated neutrophils (Fig. 2 D). Our findings indicate that one of 
two CD177 alleles is silenced during neutrophil differentia-
tion resulting in MAE in mature neutrophils. These observa-
tions support the notion that epigenetic mechanisms control 
the CD177 allele-silencing process.
epigenetic modifications control cd177 gene 
expression in a HeLa cell model
Neutrophils are short-lived and hard to transfect cells that 
are not suitable for genetic manipulation. Looking for al-
ternative cell models, we successfully induced CD177 tran-
scription in HeLa cells by phorbol myristate acetate (PMA) 
treatment (Fig.  3 A). A SNP analysis by CD177 exon and 
mRNA sequencing showed that PMA-stimulated HeLa 
cells expressed CD177 in a monoallelic fashion similar to 
CD177pos neutrophils (Fig. 3 B).
To characterize the CD177 locus, we dissected the mo-
lecular properties of the regulatory promoter region. We per-
formed 5′ RACE and determined the transcription start site 
(TSS) of the CD177 gene at 29 bp upstream of the ATG 
translation start site. In the CD177 promoter, we detected a 
GC-rich element and 16 CpG dinucleotides. We next used 
the PRO MO database (Messeguer et al., 2002) and rVIS TA 
(Loots and Ovcharenko, 2004) to predict TF binding sites in 
the promoter region of interest. We found several conserved 
binding sites for the AP-1 family members c-Jun and c-Fos 
that were shown to be involved in PMA-activated gene tran-
scription (Guerrini et al., 1996). In addition, c-Ets-1 binding 
sites were also predicted and of potential interest as a result 
of reported interactions with the AP-1 TF family (Kumari 
et al., 2015; Fig. 3 C).
First, we studied the effect of CpG-methylation on 
CD177 allele expression. We cloned the 1,373-bp full-length 
CD177 promoter with 16 CpGs, as well as shorter promoter 
regions into a CpG-dinucleotide lacking vector (Klug and 
Rehli, 2006). The constructs were used in HeLa luciferase 
reporter assays to study transcriptional activity (Fig.  3  D). 
The highest CD177 reporter activity was associated with the 
1,373 and 964 bp constructs and a significant loss of reporter 
activity was observed by shortening the construct to 178 
bp (Fig. 3 E). To address the effect of CpG-methylation on 
CD177 reporter activity, we treated constructs 1–4, each in 
the CpG-free vector, with methyltransferase. Methylation sig-
nificantly reduced reporter activity (Fig. 3 F). These findings 
indicate that CpG-methylation in CD177 regulatory pro-
moter sequence silences CD177 allele expression. In a differ-
ent approach, we treated HeLa cells with the demethylation 
agent 5-Aza-2-deoxycytidin. By CD177 mRNA sequencing, 
we found that demethylation converted monoallelic into bial-
lelic CD177 expression demonstrating that CpG-methylation 
caused indeed silencing of one CD177 allele (Fig. 3 G).
CpG-methylation affects TF binding to gene promoters. 
We performed ChIP for c-Jun, c-Fos, and c-Ets-1 on chro-
matin of PMA-stimulated HeLa cells. We found binding of 
all three TFs to CD177 promoter regions with c-Jun binding 
reaching statistical significance (Fig. 3 H). To test whether or 
not c-Jun, c-Fos, and c-Ets-1 control CD177 transcription, 
we transfected HeLa cells with the TFs and quantified CD177 
mRNA by qRT-PCR. We observed that the combination of 
c-Jun and c-Fos caused strongly induced CD177 mRNA. 
In contrast, c-Ets-1 transfection alone did not affect CD177 
transcription. Moreover, the combination of c-Ets-1 with the 
Table 1. Monoallelic cd177 expression and the allelic choice over a 7-d period in five different individuals
Individual Allele in gDNA SNP position Expressed CD177 allele
day 0 day 3 day 7
1 G/C SNP49 G G G
2 C/A SNP793 A A A
C/G SNP824 G G G
C/A SNP828 A A A
T/A SNP829 A A A
A/G SNP832 G G G
G/A SNP841 A A A
3 G/C SNP49 G G G
4 A/T SNP134 T T T
G/A SNP156 A A A
C/A SNP793 A A A
G/A SNP1333 A A A
5 C/G SNP824 G G G
C/A SNP828 A A A
T/A SNP829 A A A
A/G SNP832 G G G
G/A SNP841 A A A
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AP-1 TFs showed no additive effect (Fig. 3 I). Finally, phar-
macologic c-Jun N-terminal kinase inhibition significantly 
reduced G-CSF–induced CD177 expression in human neu-
trophils suggesting that c-Jun controls CD177 expression also 
in neutrophils (Fig. 3 J).
cpG, histone methylation, and tF binding are differentially 
regulated in the two cd177 neutrophil subsets
Our analysis established the importance of CpG methylation, 
and AP-1 TF binding in the CD177 promoter for CD177 
gene expression in HeLa cells. We reasoned that if these epi-
genetic marks provided the basis for the bimodal CD177 ex-
pression pattern in neutrophils, they should be differentially 
regulated in the two separated CD177 neutrophil subsets. 
Thus, we addressed genome-wide DNA methylation of the 
two CD177 neutrophil subsets unbiased by Illumina Infinium 
Human Methylation 450 BeadChips. The probes on this chip 
covered three of the 16 CpG-methylation sites of the CD177 
promoter and two further downstream in CD177 gene body. 
We found significantly increased CpG methylation in the 
CD177 promoter of CD177neg neutrophils (paired Student’s 
t test; Fig. 4 A and Table S2). H3K4me3 ChIP assay showed 
euchromatin in the CD177 promoter of CD177pos neutro-
phils, whereas nonenriched H3K4me3 indicated heteroch-
romatin conformation in CD177neg cells (Fig.  4  B). ChIP 
analysis revealed significantly stronger binding of c-Jun, c-Fos 
and c-Ets-1 in the CD177 promoter of CD177pos neutro-
phils, whereas no signal was obtained in the CD177neg cells 
(Fig. 4 C). In summary, our data generated in HeLa cells and 
neutrophils showed that CpG and histone methylation reg-
ulated AP-1 TF-binding in the regulatory CD177 promoter 
region thereby controlling CD177 gene expression.
dIscussIon
Our study revealed several important new findings. First, our 
haplotype studies in family trios shows monoallelic CD177 
gene expression with a novel pattern that differs from clas-
sical imprinting and random MAE. Using CD34+ HSCs, we 
observed that one CD177 allele was silenced during neu-
trophil differentiation. Second, we show that, in contrast to 
CD177pos neutrophils, the CD177neg subset transcribed nei-
ther full-length nor truncated CD177 mRNAs. Third, studies 
in HeLa cells supported the notion that CD177 allele silenc-
ing involved DNA methylation in the CD177 promoter re-
Figure 2. Monoallelic cd177 mrnA expression in neutrophil-differentiated cd34+ Hsc and neonatal neutrophils. CD34+ HSC were differentiated 
over 7 d into neutrophils and (A) acquired neutrophil surface markers CD11b and CD18, together with a bimodal CD177 phenotype. A representative flow 
cytometry analysis from four independent differentiation experiments is shown. Solid lines represent staining with the specific antibodies and dotted lines 
represent the isotype control. (B) CD177 gene expression increased progressively in CD34+ HSCs during 7 d of neutrophil differentiation (qRT-PCR; n = 4 
different CD34+ HSC donors). (C) Sanger sequencing of genomic DNA (gDNA) and mRNA from CD34+ HSC showed a heterozygous AC SNP793 (rs10425835) 
in gDNA and biallelic CD177 mRNA expression in undifferentiated cells at day 0. The C allele was silenced during neutrophil differentiation up to day 7 
(n = 4 different CD34+ HSC donors). (D) Analysis of neutrophil-differentiated CD34+ HSCs and neonatal neutrophils from the same cord blood indicate an 
informative heterozygous AC SNP793 in the gDNA from CD34+ HSCs.
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Figure 3. cd177 gene expression, promoter analysis, dnA methylation, and transcription factor binding in a HeLa cell model. (A) CD177 gene 
expression was induced in PMA-treated HeLa cells as shown by qRT-PCR (n = 3 independent experiments). (B) CD177 haplotype analysis was performed by 
Sanger sequencing the genomic DNA (gDNA) and mRNA from HeLa cells (n = 6 independent experiments). Three heterozygous SNPs in the gDNA, one in 
exon 1 (SNP49 GC) and two in exon 5 (SNP652 AG and SNP656 GT), were found and established monoallelic CD177 gene expression. (C) A schematic overview 
of the CD177 gene (red), its promoter, and the pseudogene (black) is depicted. The CD177 promoter region is enlarged.16 CpG dinucleotides, the c-Jun, 
c-Fos, and c-Ets-1 TF binding sites (PRO MO database), the TATA box, the transcription start site (TSS), the translation start (ATG), and PCR amplicons of the 
ChIPed DNA are indicated. (D) The CD177 promoter constructs P1 to P6 were cloned into the CpG-free luciferase vector. (E) Luciferase reporter assays were 
performed with the unmethylated CD177 promoter constructs P1 to P6 (n = 4 independent experiments). CD177 promoter activity was calculated from 
the firefly and Renilla luciferase signal. (F) Luciferase reporter assays were performed with P1 to P4 promoter constructs that were either left unmethylated 
(open bars) or were methylated (black bars) by incubation with methyltransferase (n = 7 independent experiments). (G) PMA-stimulated HeLa cells were 
treated with buffer (Bu) or 10 µM 5′-Aza-2-deoxycytidine (5-Aza) for 48 and 72 h, respectively (n = 6 independent experiments). Allele expression was 
analyzed using heterozygous CD177 SNPs (SNP49 rs45441892, SNP652 rs199668750, SNP656 rs200662237) in gDNA and the corresponding mRNA. Black 
indicates the percentage of experiments where monoallelic CD177 gene expression was detected and white indicates the percentage of experiments where 
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gion thereby regulating c-Jun and c-Fos binding and CD177 
gene transcription. Finally, and importantly, these mechanisms 
were differentially executed in the two CD177 neutrophil 
subsets thereby explaining the bimodal CD177 phenotype.
Almost half a century ago, clinicians were made aware 
of HNA-2 (named NB1 at that time), because alloantibod-
ies to this neutrophil antigen caused neonatal neutropenia 
(Lalezari et al., 1971). Later, researchers showed that the 
CD177 glycoprotein not only harbored the HNA-2 alloan-
tigen, but also that CD177 presented the PR3 autoantigen 
on the neutrophil surface (Bauer et al., 2007; von Vieting-
hoff et al., 2007). Alloantibodies to HNA-2 cause neutropenia 
(Lalezari et al., 1971; Stroncek et al., 1993, 1994) and TRA LI 
(Sachs et al., 2006) and autoantibodies to PR3 are associated 
with systemic small-vessel vasculitis (van der Woude et al., 
1985; Lüdemann et al., 1990). Because these conditions are 
associated with substantial mortality, understanding CD177 
expression is clinically highly relevant. Complete CD177 
deficiency is of particular interest for HNA-2 alloantibody 
generation because nonexpressers become immunized with 
pregnancies and transfusions, and the resulting alloantibod-
ies cause disease in HNA-2 expressing individuals. Investi-
gators showed that the genetic basis for CD177 deficiency 
were SNP variants leading to truncated mRNAs with pre-
mature stop codons (Kissel et al., 2002). Additionally, either 
the homozygous nonsense SNP (829T) that also resulted in 
a premature stop codon or the heterozygous SNP (829AT) 
where the 829A allele harbored an additional base deletion 
resulted in a premature stop codon (Li et al., 2015). Very re-
cently, DNA deep sequencing confirmed this homozygous 
nonsense SNP (in this study named g7497T) and found that 
the T allele was derived from gene conversion of the neigh-
boring CD177 pseudogene with the CD177 gene (Wu et al., 
2016). 6% of the individuals in our healthy Caucasian cohort 
were CD177 deficient, whereas 94% produced a variable per-
centage of CD177pos neutrophils with a median of 60%. This 
bimodal CD177 expression pattern is of particular interest 
in patients with ANCA vasculitis, where PR3 is a major au-
toantigen. Membrane-presented PR3 (mPR3) is recognized 
by PR3-ANCA that then activates the neutrophil, leading 
to vascular inflammation (Kettritz, 2012). We found previ-
ously that CD177 acts as a PR3-presenting receptor sup-
porting high mPR3 levels (von Vietinghoff et al., 2007). The 
CD177–PR3 complex recruits additional transmembrane 
molecules into a larger signaling complex (Jerke et al., 2011). 
The bimodal CD177 expression pattern therefore results in 
CD177neg/mPR3low and CD177pos/mPR3high neutrophil sub-
sets. Of clinical importance, a larger percentage of CD177pos/
mPR3high neutrophils is found in ANCA vasculitis patients 
and is associated with worse clinical outcome (Witko-Sarsat 
et al., 1999; Rarok et al., 2002; Schreiber et al., 2005; Hu et al., 
2009; Abdgawad et al., 2010). The molecular basis for the two 
distinct CD177 subsets, and therefore for the two mPR3 phe-
notypes is incompletely understood. We confirm data from 
Wolff et al. (2003), who showed that sorted CD177neg neu-
trophils from bimodal individuals lacked full-length CD177 
mRNA by PCR. We extend these data showing that multiple 
qRT-PCRs with exon-spanning primers excluded truncated 
mRNAs. In contrast, Wu et al. (2016) detected full-length 
mRNA in CD177neg sorted cells of bimodal individuals by 
deep sequencing. The differences could be related to different 
sorting algorithms and that very small amounts of contami-
nating material from CD177pos cells were analyzed by highly 
sensitive deep sequencing. Moreover, the g7497 SNP in the 
CD177neg sorted neutrophils in the Wu study was not homo-
zygous for the T allele therefore not explaining the lack of 
CD177 protein. For individuals with bimodal CD177 neu-
trophils in our study, we observed that those who were ho-
mozygous for g7497A (SNP829) and therefore harbored two 
alleles without potential stop codons showed monoallelic 
CD177 expression (Fig. S1). Another interesting phenome-
non that was not focus of our study is the occurrence of two 
CD177pos peaks. Our observations are in agreement with the 
literature in that ∼5% of individuals show this CD177 pattern 
(Moritz et al., 2010; Meyerson et al., 2013; Wu et al., 2016). 
The molecular basis of this phenomenon is unclear and needs 
to be elucidated in future studies.
MAE can follow a parent-of-origin pattern, where 
either the maternal or the paternal allele is imprinted (si-
lenced), and all cells of a specific tissue, or even of the entire 
organism, actively express exclusively the other parental allele 
(Reik and Walter, 2001; Peters, 2014). In contrast, silencing 
of one allele can occur in a random fashion first recognized 
for X chromosomes, where female cells inactivate either the 
maternal or paternal X (Lyon, 1986). Recently, it became 
clear that random MAE also occurs in ∼5–10% of the au-
tosomal loci (Gimelbrant et al., 2007). Our haplotype anal-
ysis revealed monoallelic CD177 gene expression in blood 
neutrophils, where all neutrophils of a given individual had 
uniformly silenced either their maternal or paternal CD177 
allele. This issue was best illustrated in two siblings from one 
family who both showed MAE, but had silenced the opposite 
parental allele. These findings suggest a novel MAE pattern 
not described before. It was not truly imprinting because 
biallelic CD177 allele expression was detected. (H) ChIP assays were performed using antibodies to c-Jun, c-Fos, and c-Ets-1 in PMA-stimulated HeLa cells. 
(I) Nonactivated HeLa cells were transfected with empty pcDNA3 vector, c-Jun, c-Fos, c-Ets-1, and combinations thereof (n = 3 independent experiments). 
CD177 gene expression was determined by qRT-PCR. (J) CD177 gene expression by qRT-PCR was assessed in human blood neutrophils stimulated with buf-
fer control (Bu) or 100 ng/ml G-CSF for 90 min, respectively. When indicated, G-CSF–stimulated cells were pretreated with buffer control (DMSO) or 20 µM 
JNK II inhibitor (CAS 129–56-6) for 30 min, respectively (n = 3 independent experiments). Data in A, E, F, I, and J were displayed as mean ± SEM and were 
analyzed using one-way ANO VA. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Data in H were displayed ± SEM and were analyzed using Student’s t test. *, P < 0.05.
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we observed either maternal or paternal silenced alleles. The 
pattern is also not truly random MAE because this pattern 
implies that different clonal populations derived from a par-
ticular cell type express stochastically the maternal or the pa-
ternal, and some even both alleles (Deng et al., 2014). Based 
on Sanger sequencing, together with two quantitative assays 
that used thresholds from the literature of 70% for a monoal-
lelic call (Reinius and Sandberg, 2015), we did not find a 
mixed expression of maternal and paternal alleles within the 
entire neutrophil population of a given individual. However, 
if the quantitative assays were interpreted as strongly biased 
CD177 transcriptional activity based on the inherited allele, 
two CD177pos neutrophil populations with markedly differ-
ent CD177 mRNA and protein would result. In this case, one 
would possibly expect a more skewed peak of the CD177pos 
neutrophils in the flow cytometry experiments. Neutrophils 
comprise the largest leukocyte subset with the shortest lifes-
pan and an estimated daily production rate of 1011 cells (Tak 
et al., 2013). Despite the rapid neutrophil turnover, we found 
that the allelic choice did not change over time when mea-
sured in a given individual. We observed that undifferenti-
ated CD34+ HSC, the neutrophil progenitors, transcribed 
both CD177 alleles and that one allele was silenced during 
neutrophil differentiation. Thus, the decision as to which of 
the two parental alleles is silenced has to be made 1011 times 
per day lifelong. The fact that the choice of the activated al-
lele remains constant during neutrophil differentiation and 
maturation suggests a strongly regulated silencing mechanism. 
CD177 is the first neutrophil gene shown to follow such a 
stringent and stable MAE. Interestingly, CD177 is an antigen 
receptor and the initial autosomal random MAE examples 
came from the antigen receptors of B and T cells (Pernis et 
al., 1965; Rajewsky, 1996). It was subsequently suggested that 
surface receptors are prone to autosomal MAE (Chess et al., 
1994; Pereira et al., 2003; Gimelbrant et al., 2007). Biological 
effects could be mediated either through dosage differences 
or by expressing only one out of two functionally nonequiva-
lent parental alleles. Conceptually, these effects would increase 
phenotypic variation and cellular diversity, but also harbor a 
risk when only a dysfunctional allele is expressed (Reinius and 
Sandberg, 2015). It is conceivable that MAE of CD177 has 
clinical relevance. In ANCA autoimmune vasculitis, hetero-
zygous CD177 SNPs or mutations and the choice of which 
allele is expressed could affect PR3 binding and thereby shape 
antigenicity and binding of PR3-ANCA. In fact, genes with 
MAE are particularly prone to mutations (Savova et al., 2016). 
Heterozygous CD177 mutations and the allelic choice could 
also lead to incomplete penetrance of disease phenotypes. 
Similar mechanisms could be at work for the presentation of 
CD177 alloantigen epitopes.
Figure 4. differential cpG and histone methylation, and AP-1 tF binding in the cd177 promoter of cd177neg and cd177pos neutrophil subsets. 
(A) Whole-genome DNA methylation analysis in CD177neg versus CD177pos neutrophils separated from CD177 bimodal individuals by magnetic cell sorting 
was performed using Illumina methylation chips. The localization of the 5 CpG probes (cg, CpG cluster number) within the CD177 promoter and in the 
CD177 gene that were present on the chip are indicated. Three of the five CpGs were significantly more methylated in the CD177neg neutrophils compared 
with the CD177pos subset (n = 6 different neutrophil donors). (B) ChIP assays were performed with the histone H3K4me3 mark for open chromatin in the 
CD177 promoter region of CD177pos (black lines) and CD177neg (red lines) neutrophils separated from a CD177 bimodal donor (n = 3 different neutrophil 
donors). (C) ChIP analysis for c-Jun, c-Fos, and c-Ets-1 binding was performed in CD177pos (black lines) and CD177neg (red lines) neutrophils separated from 
CD177 bimodal donors using specific antibodies to c-Jun, c-Fos, and c-Ets-1, respectively (n = 4 different neutrophil donors). Data in A, B, and C were 
analyzed using Student’s t test. *, P < 0.05; ***, P < 0.001; ±SEM is shown.
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After having excluded DNA sequence abnormalities 
and CNV, epigenetic modifications became candidates for 
allelic CD177 gene silencing (Reik and Walter, 2001; Eck-
ersley-Maslin and Spector, 2014; Reinius and Sandberg, 
2015; Gendrel et al., 2016). Neutrophils rapidly undergo 
apoptosis in vivo and in culture, preventing epigenetic 
studies in these short-lived primary cells (Fig. S2 B). To 
identify these silencing mechanisms, we took advantage 
from the observation that activated HeLa cells expressed 
CD177 in a monoallelic manner. We characterized the 
promoter region upstream of the CD177 TSS that was 
important for gene expression and contained 16 CpGs. 
Our data indicate that in vitro DNA methylation at CpG 
dinucleotides in the promoter controlled CD177 gene ex-
pression by c-Jun and c-Fos. Interestingly, pharmacologic 
HeLa cell demethylation, certainly not exclusively acting 
on the CD177 promoter, activated biallelic CD177 ex-
pression providing additional evidence for a role of DNA 
methylation in gene and single allele silencing. These data 
support the contention that DNA methylation at CpGs 
in the CD177 promoter silenced two alleles in CD177neg 
and one allele in the CD177pos neutrophil subset, respec-
tively. Most importantly, these epigenetic control mech-
anisms were differentially regulated in the two CD177 
neutrophil subsets. The promoter of the CD177neg subset 
showed significantly increased CpG and histone meth-
ylation and abrogated AP-1 TF binding. In contrast, the 
CD177pos neutrophil subset actively transcribed CD177 
in a monoallelic fashion.
In summary, we have identified DNA, histone methyla-
tion and AP-1 TF binding that control CD177 gene expres-
sion and explain the two distinct CD177 neutrophil subsets 
in bimodal individuals that are of clinical significance. In ad-
dition, we describe a novel MAE pattern for CD177 that dif-
fers from classical imprinting and random MAE in its stable 
choice of either parental allele.
MAterIALs And MetHods
neutrophil isolation
Blood neutrophils from healthy human donors were obtained 
after due approval by IRB (Institutional Charité University 
Ethics Committee, EA1/277/11 and EA3/010/06) and after 
written, informed consent, and isolated as described previ-
ously (von Vietinghoff et al., 2007).
HeLa cell culture, stimulation, and transfection
HeLa cells were cultured in DMEM supplemented with 
10% FCS, 100 U/ml penicillin, and 100 µg/ml strep-
tomycin and treated with 100 ng/ml PMA and 10 µM 
5′Aza-2-deoxycytidine (Sigma-Aldrich) as indicated. 
HeLa cells were transiently transfected with 67 ng c-Jun, 
c-Fos, and c-Ets-1 plasmids, or empty pcDNA3 vector 
control, respectively. All cells received a total of 2 µg plas-
mid using Fugene HD (Roche) according to the manu-
facturer’s instructions.
Flow cytometry and magnetic neutrophil sorting
CD177 membrane expression was assessed by flow cytom-
etry of either isolated neutrophils or in 100 µl whole blood 
after hypotonic red blood cell lysis using a FITC-labeled an-
ti-CD177 antibody (clone MEM166; Biozol) as described be-
fore (von Vietinghoff et al., 2007). CD177 neutrophil subsets 
were purified using anti-CD177 abs (clone MEM166; Exbio), 
anti-CD66b (Dako), anti-CD9 abs (Beckman Coulter), rat 
anti–mouse IgG microbeads (Miltenyi Biotech), and LD col-
umns (Miltenyi Biotech) according to the manufacturer's in-
structions. Highly pure neutrophils were prepared by density 
gradient purification, followed by depletion of CD9-positive 
eosinophils. CD177pos neutrophils were thereafter positively 
selected for CD177. CD177neg neutrophils were positively 
selected from this CD177-depleted preparation for CD66b. 
Mature neutrophil-differentiated CD34+ HSC were purified 
by FACS using a directly labeled FITC anti-CD16 antibody 
(BioLegend) and an anti-CD177 antibody (Santa Cruz Bio-
technology). When indicated neutrophils were stimulated 
with 100 µg/ml human granulocyte colony-stimulating fac-
tor (G-CSF; PeproTech) or in combination with 20 µM c-Jun 
N-terminal kinase inhibitor (JNK Inhibitor II, CAS 129–56-
6; Merck). 10  µM 5′Aza-2-deoxycytidine was performed 
as described for HeLa cells. Apoptosis was measured with 
Annexin V staining (BD) according to the manufacturer’s man-
ual and using flow cytometry.
sibling testing
DNA testing was performed by an accredited laboratory for 
forensic genetics (Institut für Medizinische Molekulare Diag-
nostik und Forensische Genetik, Berlin, Germany) using the 
Power Plex ESX-17 system (Promega).
differentiation of cd34+ stem cells from umbilical 
cord blood into neutrophils
CD34+ stem cells were isolated from cord blood, ex-
panded, and differentiated as described previously (von Vi-
etinghoff et al., 2007). Neonatal neutrophils were isolated 
from cord blood by density gradient centrifugation as de-
scribed for blood neutrophils.
Isolation of dnA, mrnA, cdnA generation, and sequencing
Total RNA was extracted using QIAzol and the RNeasy Pu-
rification kit (QIA GEN). RNA was treated by deoxyribo-
nuclease I (QIA GEN). cDNA synthesis was performed using 
hexanucleotide primers and Superscript III RT following the 
manufacturers protocol (Thermo Fisher Scientific). Genomic 
DNA was isolated using 5 M sodium perchlorate solution, 
DNA extraction by chloroform and DNA precipitation by 
isopropanol. For methylation array analysis genomic DNA 
was isolated using QIA GEN genomic DNA Isolation kit 
(QIA GEN). CD177 long templates were amplified by PCR 
using 250 ng genomic DNA, specific CD177-43.857.788-F 
and CD177-43.870.898-R primers and Elongase (Thermo 
Fisher Scientific) in a total volume of 25 µl. PCR products 
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were purified with S.N.A.P. Purification kit (Life Technol-
ogies GmbH). CD177 short products were amplified from 
20 ng of CD177 long templates or 50–100 ng cDNA with 
specific primers (Table S3) using Advantage-GC 2 PCR kit 
(Takara Bio Inc.). CD177 PCR products were sequenced 
according to Sanger method using the Big Dye Terminator 
Cycle Sequencing kit v1.1 and analyzed on a 3130xl Genetic 
Analyzer (both from Applied Biosystems). Quantitative allele 
analysis by pyrosequencing was performed by the bioanalyti-
cal services laboratory (Varionostic GmbH) using four differ-
ent SNP assays with template-specific PCR and sequencing 
primers (Table S3) and the Q24 System (QIA GEN). All SNP 
analyses were generated by PyroMark Q24 software.
Quantitative rt-Pcr
For quantitative RT-PCR (qRT-PCR) TaqMan technology 
(Applied Biosystems) was used with oligonucleotides and 
probes for human CD177 and human 18S (Table S3), and 
TaqMan Fast Universal PCR Master Mix (Applied Biosys-
tems). Each sample was measured in triplicate and expression 
levels were normalized to 18S expression. Quantification was 
performed using an Applied Biosystems 7500 Sequence de-
tector and data were analyzed using SDS 7500 software and 
ΔΔCt comparative analysis as described by Applied Biosystems.
digital Pcr
Quantification of allele-specific mRNA expression was 
performed using the QuantStudio 3D Digital PCR Sys-
tem (Thermo Fisher Scientific). SNP49 (rs45441892) was 
detected by the human TaqMan SNP Genotyping Assay 
C_27850890_10 and SNP156 (rs45571738) by the human 
TaqMan SNP Genotyping Assay C_27837236_10, respec-
tively. Each reaction mix for one QuantStudio 3D Digital 
PCR chip v2 consisted of QuantStudio 3D Digital PCR 
Master Mix v2 (Thermo Fisher Scientific), specific human 
TaqMan SNP Genotyping Assay (primer/probe mix), tem-
plate cDNA or gDNA with final concentration at 3.45 ng/µl 
and PCR-grade water in a final volume of 14.5 µl. PCR con-
ditions were as follows: stage 1 enzyme activation, 96°C for 
10 min; stage 2 annealing/extension and new denaturation at 
54°C (SNP49) or 58°C (SNP156) for 2 min and 98°C for 30 s 
(39 cycles); stage 3 annealing/extension 60°C for 2 min and 
storage at 10°C. Each sample was analyzed using a separate 
20,000 times compartmented QuantStudio 3D Digital PCR 
chip v2 and the AnalysisSuite Software (Thermo Fisher Sci-
entific). The expressed allele amounts were presented as copy 
numbers per microliter PCR mixture.
dnA and cdnA sequencing
DNA and cDNA sequencing was performed from the 
CD177 PCR products treated with shrimp alkaline phospha-
tase (SAP; Affymetrix) and exonuclease I (NEB). After en-
zyme inactivation, the PCR products were subjected to DNA 
sequencing using BigDye Terminator v1.1 Cycle Sequencing 
kit from Applied Biosystems. Purification of the samples was 
done with ZR DNA Sequencing Clean-up kit (ZYMO Re-
search). DNA sequencing was performed with a 16-capillary 
sequencer 3130xl Genetic Analyzer (Applied Biosystems).
5′ rAce Pcr
5′ RACE PCR was performed from neutrophil total RNA 
using QIAzol (QIA GEN), the GeneRacer kit, specific prim-
ers (Table S3), and reverse transcribed using Superscript III 
RT (Life Technologies GmbH). PCR fragments were cloned 
into a pDrive vector (QIA GEN) and sequenced as described 
in the previous section.
dnA methylation analysis
Genomic DNA was purified by using QIA GEN genomic 
DNA Isolation kit (QIA GEN). Genome-wide methylation 
analysis was performed by LIFE & BRA IN GmbH using an 
Infinium Human Methylation 450 BeadChip (Illumina).
sds-PAGe, coomassie staining, and immunoblot analysis
Cell lysis, SDS-PAGE, and immunoblots were performed as 
previously described (Jerke et al., 2015). Immunoblots were 
developed with a monoclonal rabbit anti-PR3 antibody 
(clone 4A5; Wieslab), an anti-CD177 mAb (clone MEM166, 
Exbio), or a polyclonal anti-CD177 (R&D Systems) as in-
dicated and visualized by enhanced chemiluminescence 
(Thermo Fisher Scientific).
reporter assays
104 cells per well were seeded into 96-well plates 24 h before 
transfection. HeLa cells were transiently transfected with the 
indicated CD177 promoter plasmids, as well as with empty 
CpG-free methylation vector in equal molarities (55.14 
amol). The CD177 promoter luciferase constructs were 
transfected with Fugene HD according to the manufactur-
er’s recommendations (Roche). For controlling the transfec-
tion efficiency, we transfected each well with 8 ng pRL-TK 
(Promega). Cell lysates were analyzed using the Dual-Lucifer-
ase Reporter Assay System (Promega) and the Infinite M200 
PRO Multimode Microplate Reader from Tecan. To normal-
ize reporter data, a quotient of the luciferase and the Renilla 
signal was calculated for each well.
chromatin immunoprecipitation
3 × 107 neutrophils or 3 × 107 PMA-stimulated HeLa 
cells were treated with 0.4% formaldehyde to cross-link 
proteins and DNA. Chromatin was sonicated with Bio-
ruptor Plus sonication device (Diagenode). 4 × 107 mag-
netic Dynabeads M-280 sheep anti–rabbit IgG (Thermo 
Fisher Scientific) were overnight preincubated with 5 µg 
anti-H3K4me3, 10 µg anti–c-Jun, 10 µg anti-c-Fos, 10 µg 
anti–c-Ets-1 or 5 µg/10 µg anti-IgG control ChIP-tested 
antibodies (Abcam). After washing of Dynabead-antibody 
samples, 50 µg chromatin was added to each sample and 
incubated overnight. 1 and 10% of the chromatin sam-
ples served as input. Antibody-Dynabeads bound DNA 
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was eluted in 1% SDS buffer and incubated with RNase 
A (Thermo Fisher Scientific) and Proteinase K (NEB). 
DNA was isolated by phenol/chloroform extraction and 
analyzed by quantitative RT-PCR using Fast SYBR Green 
Master Mix and specific and control primers (Table S3) on 
an ABI Prism 7500 Fast System (Applied Biosystems). The 
relative signals of the specific PCR product was expressed 
as percent of input chromatin using raw Ct values and was 
normalized for the control IgG.
statistical analysis
Results are given as mean ± SEM. Comparisons between 
multiple groups were done using ANO VA and appropriate 
post-hoc tests or differences between experimental groups 
were analyzed by Student’s t test. Differences were consid-
ered significant if P < 0.05. The dPCR results were given as 
poisson plus ratio with confidence intervals according to the 
AnalysisSuite Software (Thermo Fisher Scientific).
online supplemental material
Fig. S1 shows the genome-wide single nucleotide polymor-
phisms (SNPs) analysis of sorted CD177neg and CD177pos 
neutrophil subsets and the haplotype analysis of the CD177 
gene. Fig. S2 presents haplotype analyses and sibling testing 
of an informative family with respect to the allelic choice of 
the CD177 MAE as well as 5-Aza-2-deoxycytidin (5-Aza) 
treatment of primary human neutrophils. Table S1 lists SNPs 
identified in the CD177 exons by sequencing. Table S2 shows 
probes in the CD177 promoter and gene body that are cov-
ered by the Methylation450 Bead Chip. Table S3 lists all oli-
gonucleotides for PCR assays.
AcknoWLedGMents
We thank Prof. Dr. Michael Rehli (Department of Internal Medicine III, University 
Hospital Regensburg, F.-J.-Strauss Allee 11, D-93053 Regensburg) for the CpG free 
luciferase reporter vector.
This work was supported by DFG grant KE 576/8-1 and an ECRC grant.
The authors declare no competing financial interests.
Author contributions: R. Kettritz, S. Bähring, P.G. Maass, and C. Eulen-
berg-Gustavus designed experiments and analyzed data. C. Eulenberg-Gustavus per-
formed experiments and P.G. Maass and S. Bähring assisted with experiments. R. 
Kettritz and C. Eulenberg-Gustavus wrote the manuscript and R. Kettritz funded the 
study. F.C. Luft, P.G. Maass, S. Bähring, R. Kettritz, and C. Eulenberg-Gustavus re-
vised the manuscript.
Submitted: 13 July 2016
Revised: 1 February 2017
Accepted: 12 April 2017
reFerences
Abdgawad, M., L. Gunnarsson, A.A. Bengtsson, P. Geborek, L. Nilsson, M. 
Segelmark, and T. Hellmark. 2010. Elevated neutrophil membrane ex-
pression of proteinase 3 is dependent upon CD177 expression. Clin. Exp. 
Immunol. 161:89–97.
Barlow, D.P., and M.S. Bartolomei. 2014. Genomic imprinting in mammals. 
Cold Spring Harb. Perspect. Biol. 6:5–10. http ://dx .doi .org /10 .1101 /
cshperspect .a018382
Bauer, S., M. Abdgawad, L. Gunnarsson, M. Segelmark, H. Tapper, and T. 
Hellmark. 2007. Proteinase 3 and CD177 are expressed on the plasma 
membrane of the same subset of neutrophils. J. Leukoc. Biol. 81:458–464. 
http ://dx .doi .org /10 .1189 /jlb .0806514
Bayat, B., S. Werth, U.J.H. Sachs, D.K. Newman, P.J. Newman, and S. Santoso. 
2010. Neutrophil transmigration mediated by the neutrophil-specific 
antigen CD177 is influenced by the endothelial S536N dimorphism 
of platelet endothelial cell adhesion molecule-1. J. Immunol. 184:3889–
3896. http ://dx .doi .org /10 .4049 /jimmunol .0903136
Bettinotti, M.P., A. Olsen, and D. Stroncek. 2002. The use of bioinformatics 
to identify the genomic structure of the gene that encodes neutrophil 
antigen NB1, CD177. Clin. Immunol. 102:138–144. http ://dx .doi .org 
/10 .1006 /clim .2001 .5154
Bux, J., F. Becker, W. Seeger, D. Kilpatrick, J. Chapman, and A. Waters. 1996. 
Transfusion-related acute lung injury due to HLA-A2-specific antibodies 
in recipient and NB1-specific antibodies in donor blood. Br. J. Haematol. 
93:707–713. http ://dx .doi .org /10 .1046 /j .1365 -2141 .1996 .d01 -1703 .x
Caruccio, L., M. Bettinotti, A.E. Director-Myska, D.C. Arthur, and D. 
Stroncek. 2006. The gene overexpressed in polycythemia rubra vera, 
PRV-1, and the gene encoding a neutrophil alloantigen, NB1, are alleles 
of a single gene, CD177, in chromosome band 19q13.31. Transfusion. 
46:441–447. http ://dx .doi .org /10 .1111 /j .1537 -2995 .2006 .00741 .x
Chess, A., I. Simon, H. Cedar, and R. Axel. 1994. Allelic inactivation regulates 
olfactory receptor gene expression. Cell. 78:823–834. http ://dx .doi .org 
/10 .1016 /S0092 -8674(94)90562 -2
Deng, Q., D. Ramsköld, B. Reinius, and R. Sandberg. 2014. Single-cell RNA-
seq reveals dynamic, random monoallelic gene expression in mammalian 
cells. Science. 343:193–196. http ://dx .doi .org /10 .1126 /science .1245316
Eckersley-Maslin, M.A., and D.L. Spector. 2014. Random monoallelic 
expression: regulating gene expression one allele at a time. Trends Genet. 
30:237–244. http ://dx .doi .org /10 .1016 /j .tig .2014 .03 .003
Gendrel, A.V., L. Marion-Poll, K. Katoh, and E. Heard. 2016. Random 
monoallelic expression of genes on autosomes: Parallels with 
X-chromosome inactivation. Semin. Cell Dev. Biol. 56:100–110. http ://
dx .doi .org /10 .1016 /j .semcdb .2016 .04 .007
Gimelbrant, A., J.N. Hutchinson, B.R. Thompson, and A. Chess. 2007. 
Widespread monoallelic expression on human autosomes. Science. 
318:1136–1140. http ://dx .doi .org /10 .1126 /science .1148910
Goldschmeding, R., C.M. van Dalen, N. Faber, J. Calafat, T.W. Huizinga, C.E. 
van der Schoot, L.T. Clement, and A.E. von dem Borne. 1992. Further 
characterization of the NB 1 antigen as a variably expressed 56-62 kD 
GPI-linked glycoprotein of plasma membranes and specific granules of 
neutrophils. Br. J. Haematol. 81:336–345. http ://dx .doi .org /10 .1111 /j 
.1365 -2141 .1992 .tb08237 .x
Guerrini, L., L. Casalino, A. Corti, and F. Blasi. 1996. NF-kappa B-mediated 
regulation of urokinase gene expression by PMA and TNF-alpha in 
human A549 cells. FEBS Lett. 393:69–73. http ://dx .doi .org /10 .1016 
/0014 -5793(96)00854 -X
Hu, N., J. Westra, M.G. Huitema, M. Bijl, E. Brouwer, C.A. Stegeman, P. 
Heeringa, P.C. Limburg, and C.G. Kallenberg. 2009. Coexpression of 
CD177 and membrane proteinase 3 on neutrophils in antineutrophil 
cytoplasmic autoantibody-associated systemic vasculitis: anti-proteinase 
3-mediated neutrophil activation is independent of the role of CD177-
expressing neutrophils. Arthritis Rheum. 60:1548–1557. http ://dx .doi 
.org /10 .1002 /art .24442
Jerke, U., S. Rolle, G. Dittmar, B. Bayat, S. Santoso, A. Sporbert, F. Luft, and 
R. Kettritz. 2011. Complement receptor Mac-1 is an adaptor for NB1 
(CD177)-mediated PR3-ANCA neutrophil activation. J. Biol. Chem. 
286:7070–7081. http ://dx .doi .org /10 .1074 /jbc .M110 .171256
CD177 genetics | Eulenberg-Gustavus et al.2100
Jerke, U., D.P. Hernandez, P. Beaudette, B. Korkmaz, G. Dittmar, and R. 
Kettritz. 2015. Neutrophil serine proteases exert proteolytic activity on 
endothelial cells. Kidney Int. 88:764–775. http ://dx .doi .org /10 .1038 /ki 
.2015 .159
Kettritz, R. 2012. How anti-neutrophil cytoplasmic autoantibodies activate 
neutrophils. Clin. Exp. Immunol. 169:220–228. http ://dx .doi .org /10 
.1111 /j .1365 -2249 .2012 .04615 .x
Kissel, K., S. Santoso, C. Hofmann, D. Stroncek, and J. Bux. 2001. Molecular 
basis of the neutrophil glycoprotein NB1 (CD177) involved in the 
pathogenesis of immune neutropenias and transfusion reactions. 
Eur. J. Immunol. 31:1301–1309. http ://dx .doi .org /10 .1002 /1521 
-4141(200105)31 :5<1301::AID-IMMU1301>3.0.CO;2-J
Kissel, K., S. Scheffler, M. Kerowgan, and J. Bux. 2002. Molecular basis of 
NB1 (HNA-2a, CD177) deficiency. Blood. 99:4231–4233. http ://dx .doi 
.org /10 .1182 /blood .V99 .11 .4231
Klug, M., and M. Rehli. 2006. Functional analysis of promoter CpG 
methylation using a CpG-free luciferase reporter vector. Epigenetics. 
1:127–130. http ://dx .doi .org /10 .4161 /epi .1 .3 .3327
Kuckleburg, C.J., S.B. Tilkens, S. Santoso, and P.J. Newman. 2012. Proteinase 
3 contributes to transendothelial migration of NB1-positive neutrophils. 
J. Immunol. 188:2419–2426. http ://dx .doi .org /10 .4049 /jimmunol 
.1102540
Kumari, S., M. Saradhi, M. Rana, S. Chatterjee, M. Aumercier, G. 
Mukhopadhyay, and R.K. Tyagi. 2015. Pregnane and Xenobiotic 
Receptor gene expression in liver cells is modulated by Ets-1 in 
synchrony with transcription factors Pax5, LEF-1 and c-Jun. Exp. Cell 
Res. 330:398–411. http ://dx .doi .org /10 .1016 /j .yexcr .2014 .09 .020
Lalezari, P., G.B. Murphy, and F.H. Allen Jr. 1971. NB1, a new neutrophil-
specific antigen involved in the pathogenesis of neonatal neutropenia. J. 
Clin. Invest. 50:1108–1115. http ://dx .doi .org /10 .1172 /JCI106582
Li, Y., D.C. Mair, R.M. Schuller, L. Li, and J. Wu. 2015. Genetic mechanism of 
human neutrophil antigen 2 deficiency and expression variations. PLoS 
Genet. 11:e1005255. http ://dx .doi .org /10 .1371 /journal .pgen .1005255
Loots, G.G., and I. Ovcharenko. 2004. rVIS TA 2.0: evolutionary analysis 
of transcription factor binding sites. Nucleic Acids Res. 32(Web 
Server):W217-21. http ://dx .doi .org /10 .1093 /nar /gkh383
Lüdemann, J., B. Utecht, and W.L. Gross. 1990. Anti-neutrophil cytoplasm 
antibodies in Wegener’s granulomatosis recognize an elastinolytic 
enzyme. J. Exp. Med. 171:357–362. http ://dx .doi .org /10 .1084 /jem .171 
.1 .357
Lyon, M.F. 1986. X chromosomes and dosage compensation. Nature. 320:313. 
http ://dx .doi .org /10 .1038 /320313b0
Matsuo, K., A. Lin, J.L. Procter, L. Clement, and D. Stroncek. 2000. Variations 
in the expression of granulocyte antigen NB1. Transfusion. 40:654–662. 
http ://dx .doi .org /10 .1046 /j .1537 -2995 .2000 .40060654 .x
Messeguer, X., R. Escudero, D. Farré, O. Núñez, J. Martínez, and M.M. Albà. 
2002. PRO MO: detection of known transcription regulatory elements 
using species-tailored searches. Bioinformatics. 18:333–334. http ://dx .doi 
.org /10 .1093 /bioinformatics /18 .2 .333
Meyerson, H.J., E. Osei, K. Schweitzer, G. Blidaru, A. Edinger, and A. Balog. 
2013. CD177 expression on neutrophils: in search of a clonal assay for 
myeloid neoplasia by flow cytometry. Am. J. Clin. Pathol. 140:658–669. 
http ://dx .doi .org /10 .1309 /AJC PDF BEB QZW1OI7
Moritz, E., A.K. Chiba, E.Y. Kimura, D. Albuquerque, F.P. Guirão, M. 
Yamamoto, F.F. Costa, and J.O. Bordin. 2010. Molecular studies reveal 
that A134T, G156A and G1333A SNPs in the CD177 gene are 
associated with atypical expression of human neutrophil antigen-2. Vox 
Sang. 98:160–166. http ://dx .doi .org /10 .1111 /j .1423 -0410 .2009 .01233 
.x
Pereira, J.P., R. Girard, R. Chaby, A. Cumano, and P. Vieira. 2003. Monoallelic 
expression of the murine gene encoding Toll-like receptor 4. Nat. 
Immunol. 4:464–470. http ://dx .doi .org /10 .1038 /ni917
Pernis, B., G. Chiappino, A.S. Kelus, and P.G. Gell. 1965. Cellular localization 
of immunoglobulins with different allotypic specificities in rabbit 
lymphoid tissues. J. Exp. Med. 122:853–876. http ://dx .doi .org /10 .1084 
/jem .122 .5 .853
Peters, J. 2014. The role of genomic imprinting in biology and disease: an 
expanding view. Nat. Rev. Genet. 15:517–530. http ://dx .doi .org /10 
.1038 /nrg3766
Rajewsky, K. 1996. Clonal selection and learning in the antibody system. 
Nature. 381:751–758. http ://dx .doi .org /10 .1038 /381751a0
Rarok, A.A., C.A. Stegeman, P.C. Limburg, and C.G.M. Kallenberg. 2002. 
Neutrophil membrane expression of proteinase 3 (PR3) is related to 
relapse in PR3-ANCA-associated vasculitis. J. Am. Soc. Nephrol. 13:2232–
2238. http ://dx .doi .org /10 .1097 /01 .ASN .0000028642 .26222 .00
Reik, W., and J. Walter. 2001. Genomic imprinting: parental influence on the 
genome. Nat. Rev. Genet. 2:21–32. http ://dx .doi .org /10 .1038 /35047554
Reinius, B., and R. Sandberg. 2015. Random monoallelic expression of 
autosomal genes: stochastic transcription and allele-level regulation. Nat. 
Rev. Genet. 16:653–664. http ://dx .doi .org /10 .1038 /nrg3888
Rørvig, S., O. Østergaard, N.H. Heegaard, and N. Borregaard. 2013. Proteome 
profiling of human neutrophil granule subsets, secretory vesicles, and 
cell membrane: correlation with transcriptome profiling of neutrophil 
precursors. J. Leukoc. Biol. 94:711–721. http ://dx .doi .org /10 .1189 /jlb 
.1212619
Sachs, U.J., K. Hattar, N. Weissmann, R.M. Bohle, T. Weiss, U. Sibelius, and 
J. Bux. 2006. Antibody-induced neutrophil activation as a trigger for 
transfusion-related acute lung injury in an ex vivo rat lung model. Blood. 
107:1217–1219. http ://dx .doi .org /10 .1182 /blood -2005 -04 -1744
Sachs, U.J., C.L. Andrei-Selmer, A. Maniar, T. Weiss, C. Paddock, V.V. Orlova, 
E.Y. Choi, P.J. Newman, K.T. Preissner, T. Chavakis, and S. Santoso. 
2007. The neutrophil-specific antigen CD177 is a counter-receptor 
for platelet endothelial cell adhesion molecule-1 (CD31). J. Biol. Chem. 
282:23603–23612. http ://dx .doi .org /10 .1074 /jbc .M701120200
Savova, V., S. Chun, M. Sohail, R.B. McCole, R. Witwicki, L. Gai, T.L. 
Lenz, C.T. Wu, S.R. Sunyaev, and A.A. Gimelbrant. 2016. Genes with 
monoallelic expression contribute disproportionately to genetic diversity 
in humans. Nat. Genet. 48:231–237. http ://dx .doi .org /10 .1038 /ng .3493
Schreiber, A., B. Otto, X. Ju, M. Zenke, U. Goebel, F.C. Luft, and R. Kettritz. 
2005. Membrane proteinase 3 expression in patients with Wegener’s 
granulomatosis and in human hematopoietic stem cell-derived 
neutrophils. J. Am. Soc. Nephrol. 16:2216–2224. http ://dx .doi .org /10 
.1681 /ASN .2004070609
Stroncek, D.F. 2007. Neutrophil-specific antigen HNA-2a, NB1 glycoprotein, 
and CD177. Curr. Opin. Hematol. 14:688–693. http ://dx .doi .org /10 
.1097 /MOH .0b013e3282efed9e
Stroncek, D.F., R.S. Shapiro, A.H. Filipovich, L.B. Plachta, and M.E. Clay. 1993. 
Prolonged neutropenia resulting from antibodies to neutrophil-specific 
antigen NB1 following marrow transplantation. Transfusion. 33:158–163. 
http ://dx .doi .org /10 .1046 /j .1537 -2995 .1993 .33293158050 .x
Stroncek, D.F., G.P. Herr, R.B. Maguire, G. Eiber, and L.T. Clement. 1994. 
Characterization of the neutrophil molecules identified by quinine-
dependent antibodies from two patients. Transfusion. 34:980–985. http 
://dx .doi .org /10 .1046 /j .1537 -2995 .1994 .341195065037 .x
Tak, T., K. Tesselaar, J. Pillay, J.A. Borghans, and L. Koenderman. 2013. What’s 
your age again? Determination of human neutrophil half-lives revisited. 
J. Leukoc. Biol. 94:595–601. http ://dx .doi .org /10 .1189 /jlb .1112571
van der Woude, F.J., N. Rasmussen, S. Lobatto, A. Wiik, H. Permin, L.A. 
van Es, M. van der Giessen, G.K. van der Hem, and T.H. The. 1985. 
Autoantibodies against neutrophils and monocytes: tool for diagnosis 
and marker of disease activity in Wegener’s granulomatosis. Lancet. 
1:425–429. http ://dx .doi .org /10 .1016 /S0140 -6736(85)91147 -X
von Vietinghoff, S., G. Tunnemann, C. Eulenberg, M. Wellner, M. Cristina 
Cardoso, F.C. Luft, and R. Kettritz. 2007. NB1 mediates surface expression 
2101JEM Vol. 214, No. 7
of the ANCA antigen proteinase 3 on human neutrophils. Blood. 
109:4487–4493. http ://dx .doi .org /10 .1182 /blood -2006 -10 -055327
von Vietinghoff, S., C. Eulenberg, M. Wellner, F.C. Luft, and R. Kettritz. 2008. 
Neutrophil surface presentation of the anti-neutrophil cytoplasmic 
antibody-antigen proteinase 3 depends on N-terminal processing. Clin. 
Exp. Immunol. 152:508–516. http ://dx .doi .org /10 .1111 /j .1365 -2249 
.2008 .03663 .x
Witko-Sarsat, V., P. Lesavre, S. Lopez, G. Bessou, C. Hieblot, B. Prum, L.H. 
Noël, L. Guillevin, P. Ravaud, I. Sermet-Gaudelus, et al. 1999. A large 
subset of neutrophils expressing membrane proteinase 3 is a risk factor 
for vasculitis and rheumatoid arthritis. J. Am. Soc. Nephrol. 10:1224–1233.
Wolff, J., C. Brendel, L. Fink, R.M. Bohle, K. Kissel, and J. Bux. 2003. Lack of 
NB1 GP (CD177/HNA-2a) gene transcription in NB1 GP-neutrophils 
from NB1 GP-expressing individuals and association of low expression 
with NB1 gene polymorphisms. Blood. 102:731–733. http ://dx .doi .org 
/10 .1182 /blood -2002 -09 -2831
Wu, Z., R. Liang, T. Ohnesorg, V. Cho, W. Lam, W.P. Abhayaratna, P.A. Gatenby, 
C. Perera, Y. Zhang, B. Whittle, et al. 2016. Heterogeneity of Human 
Neutrophil CD177 Expression Results from CD177P1 Pseudogene 
Conversion. PLoS Genet. 12:e1006067. http ://dx .doi .org /10 .1371 /
journal .pgen .1006067
T
h
e
 J
o
u
r
n
a
l 
o
f 
E
x
p
e
r
im
e
n
t
a
l 
M
e
d
ic
in
e
S15JEM 
SUPPLEMENTAL MATERIAL
Eulenberg-Gustavus et al., https ://doi .org /10 .1084 /jem .20161093
CD177 genetics | Eulenberg-Gustavus et al.S16
Figure S1. Genome-wide SNPs analysis of CD177neg and CD177pos neutrophil subsets and haplotype analysis of the CD177 gene. (A) Ge-
nome-wide SNP analysis using an Affimetrix SNP array 6.0 was performed in the two sorted CD177 neutrophil subsets from five different individuals. 
Shown are the number of SNPs called and the number of concordant SNPs between the two subsets in a given individual (five biological replicates, 99.9% 
concordance by Fisher’s exact test). (B) Haplotype analysis of the CD177 gene. Analyses were performed in 12 families with 17 offspring, and (C) 9 additional 
individuals. 13 SNPs are depicted in the haplotype analysis that were selected because they were informative with respect to the allelic choice in at least 
one trio. The informative parental haplotype that is inherited by the offspring is boxed in light orange (maternal) and blue (paternal), and the SNP positions 
are indicated. SNPs that were informative for the allelic choice in a given trio are marked in red. Individuals numbered 1–19 are homozygous for g7497A 
(SNP829). Note that these individuals had several informative SNPs indicating monoallelic CD177 expression (see Discussion).
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Figure S2. Haplotype analysis, sibling testing of an informative family with respect to the allelic choice of the CD177 MAE, and 
5-Aza-2-deoxycytidin (5-Aza) treatment of primary human neutrophils. (A) Haplotype analysis of a family with two siblings. The informative pa-
rental haplotype that is inherited by the offspring is boxed in light orange (maternal) and blue (paternal). SNPs that were informative for the allelic choice 
are marked in red. One offspring showed MAE of the paternal (left) and one of the maternal allele (right). The corresponding tables show the microsatellite 
markers obtained by Power Plex ESX-17 for both offspring establishing full-sibling status. Red and blue color-coding as described above. (B) Primary human 
neutrophils were treated with buffer (Bu) or 10 µM 5-Aza-2-deoxycytidin (5-Aza) for 24 h and 48 h, respectively. The percentage of Annexin V–positive 
apoptotic neutrophils was assessed by flow cytometry, and histograms are depicted. mRNA was purified and subjected to CD177 PCR. Freshly isolated cells, 
but not 5-Aza–treated cells, showed a PCR product. One of two representative experiments is given.
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Table S1. SNPs identified in the CD177 exons by sequencing
SNP position Allele SNP-ID no. Location in the CD177 gene Genomic position on chromosome 19 (hg19)
SNP49 G/C rs45441892 exon 1 43.857.873-43.857.873
SNP134 A/T rs45553433 exon 2 43.858.044-43.858.044
SNP156 G/A rs45571738 exon 2 43.858.066-43.858.066
SNP387 C/T no exon 3 43.858.510-43.858.510
SNP462 A/T no exon 4 43.859.853-43.859.853
SNP488 A/T no exon 4 43.859.879-43.859.879
SNP593 T/G rs71337594 exon 5 43.860.192-43.860.192
SNP652 G/A rs199668750 exon 5 43.860.251-43.860.251
SNP656 T/G rs200662237 exon 5 43.860.255-43.860.255
SNP664 T/G rs73559882 exon 6 43.864.419-43.864.419
SNP667 C/T no exon 6 43.864.422-43.864.422
SNP752 T/C rs57802244 exon 6 43.864.507-43.864.507
SNP793 C/A rs10425835 exon 6 43.864.548-43.864.548
SNP798 T/C no exon 6 43.864.553-43.864.553
SNP824 C/G rs200660811 exon 7 43.865.316-43.865.316
SNP828 C/A rs587670082 exon 7 43.865.320-43.865.320
SNP829 T/A rs201821720 exon 7 43.865.321-43.865.321
SNP832 A/G rs200145410 exon 7 43.865.324-43.865.324
SNP841 G/A rs201266439 exon 7 43.865.333-43.865.333
SNP1084 G/A rs61625631 exon 8 43.865.692-43.865.692
SNP1114 C/T rs61002457 exon 8 43.865.722-43.865.722
SNP1333 A/C/G/T rs78718189 exon 9 43.866.449-43.866.449
SNP-ID is SNP identification number. SNP used for haplotype analysis are shown in bold.
Table S2. Probes in the CD177 promoter and gene body that are covered by the Illumina Infinium HumanMethylation450 BeadChips used for 
genome-wide DNA methylation
Probe name P-value Student’s t test Mean (N) Mean (P) Mean ratio 
(N/P)
Mean diff 
(N-P)
UCSC ref gene hg19 (bps) chr.19
cg22537604 7.10E-07 30.51 0.94 -0.80 3.3 1.74 CD177 43857074
cg15742245 2.98E-05 14.33 2.80 1.07 3.3 1.73 CD177 43857717
cg12032655 3.64E-05 13.76 -0.49 -1.58 2.1 1.09 CD177 43856746
cg05275595 4.92E-04 8.00 0.38 -0.21 1.5 0.59 CD177 43857874
cg11906444 4.44E-01 -0.83 1.57 1.64 1.0 -0.07 CD177 43858174
cg means CpG cluster number.
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Table S3. Oligonucleotides for PCR assays
Name 5′-3′ sequence
RACE Abridged Anchor Primer GGC CAC GCG TCG ACT AGT ACG GGI IGG GII GGG IIG
Abridged Universal Primer GGC CAC GCG TCG ACT AGT AC
Universal Amplification Primer CUA CUA CUA CUA GGC CAC GCG TCG ACT AGT AC
5′ RACE CD177-102R CAC TCC TGG CAG TGG GAG GAT GAA
5′ RACE CD177-265R CCT TGG AGA GCA CCA GGC TCA CTT
5′ RACE CD177-616R GTG TCC CAT TGA GCA GGT TGC AAA CT
qRT-PCR human CD177-F TTG ATG CTC ATT GAG AGC GG
qRT-PCR human CD177-R GCC TCC GTG CAG CCCT
qRT-PCR human CD177-probe FAM-CCC CAA GTG AGC CTG GTG CTC TCC-TAM RA
qRT-PCR human 18S-F ACA TCC AAG GAA GGC AGC AG
qRT-PCR human 18S-R TTT TCG TCA CTA CCT CCC CG
qRT-PCR human 18S-probe FAM-CGC GCA AAT TAC CCA CTC CCG AC-TAM RA
CD177-43.857.788-F GCT GGC TGC TTA AGG GCT GGT ATAA
CD177-43.870.898-R CAT CCT GTA CGG GGA AAT CAG ACT TG
CD177-43.857.825-F CTG CTG AAA AAG CAG AAA GAGA
CD177-43.858.437-R ATC CGG TGC TCA GTG ACG
CD177-43.858.316-F AGG CCT GAC CTC CAT CCT
CD177-43.859.013-R CTG TGT TCA CAA GCT GTT CCA
CD177-43.859.487-F AAC TCC TGA CCT CGT GAT CC
CD177-43.860.178-R GCA TCC CTG GAC TCT CAG AT
CD177-43.860.080-F CTC TGA GGG TTG GGT GGTC
CD177-43.860.770-R CCA CCA TGG CTT CCT GTT
CD177-43.864.250-F TGG GAT TTC GAC TCC CAA GT
CD177-43.864.943-R TGT TTG TTT CCT GTT TCT CAA GG
CD177-43.864.829-F TCA GTG GCT TCA TAC ATT CTGG
CD177-43.865.520-R GTG TCT GGG CCT CAT TTC TC
CD177-43.865.418-F CCT CGG ACC TGT GCA ATA GT
CD177-43.866.126-R AGC TCC AGC TCC TCA GACC
CD177-43.866.021-F CTC TGG ACT CCT GGG TCT GA
CD177-43.866.676-R CCT CTC CCA TAG GGC AAG TC
CD177-43.857.862-F GGG TCA TGA GCG CGG TAT TAC
CD177-43.864.453-F CAC ACG GAA ACT TGG CTC AAG AAC
CD177-43.865.382-R GGA GGG GCT GAG TGG ATG GTGG
CD177-43.865.688-F GGG CGC CAC TCA TTG TTA TG
CD177-43.866.478-R ATA GAG TTA GCA GGA AGG GCA AAC
Pyro-SNP49-134-156-F AGC CAC AGA CGG GTC ATG AG
Biotin-Pyro-SNP49-134-156-R Biotin-CTG GTG TTC TTA GGG GTC CAT TG
PyroSeq-SNP49-134-156-F AGA CGG GTC ATG AGC
Pyro-SNP462-488-F AAC TCC CTC CCG CTT TGG
Biotin-Pyro-SNP462-488-R Biotin-GGT CCC CTT GGG GCA GAT
PyroSeq-SNP462-488-F CCA GTC TGC TTG TCT ATG
Pyro-SNP793-F GGC AGG TGT GTC AGG AGAC
Biotin-Pyro-SNP793-R Biotin-CCA GGG TTG ATG TGA GTC CTAC
PyroSeq-SNP793-F GAG ACG CTG CTG CTC
Biotin-Pyro-SNP1084-F Biotin-GCT CCC CCC GAA TGA CCT
Pyro-SNP1084-R AGC CCA CCT CCT GAG AGA TGA
PyroSeq-SNP1084-F CCA TCA TAA CAA TGA GTGG
Luciferase-P1-F TGC GTG GGA ATC CGC CTT CCC TCT TCT GCT TCT
Luciferase-P2-F TGC GTG GGA TCC TCC TGG TGG TAG GAA ACT GG
Luciferase-P3-F TGC GTG GGA TCC GGG TCA AGA TGC CAC AGT TT
Luciferase-P4-F TGC GTG GGA TCC AAG AAA GGG GGT CCC TGA TAG
Luciferase-P5-F TGC GTG GGA TCC GGC TGC TTA AGG GCT GGT AT
Luciferase-P6-F TGC GTG GGA TCC GTC ATG AGC GCG GTA TTA CT
Luciferase-R CAC GCA GGA TCC CAC AGG GAT CAA GGG ACT GA
M13-For GTA AAA CGA CGG CCAG
M13-Rev CAG GAA ACA GCT ATG AC
ChIP1–43.856.451-F TTG CAA GTC ACA TTC ATT TCT CT
ChIP1–43.856.582-R AGG AAG GAA CCT GGG GTA TCT
ChIP2–43.857.044-F GGG AAG ACA GTG GAG GGT AGA
ChIP2–43.857.159-R CCA CCT CTG TAC CCC AGA TG
ChIP3–43.857.186-F ACT GCC TTC CCA AAC TAC TGG
ChIP3–43.857.307-R AGA AAC TGT GGC ATC TTG ACC
ChIP4–43.857.630-F GTC CTG GAC CCT CCA TCTG
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Name 5′-3′ sequence
ChIP4–43.857.720-R GCC GCA GTG GCC TAT CAG
ChIP5–43.857.792-F GCT GCT TAA GGG CTG GTA TAAA
ChIP5–43.857.896-R CAG GAG GGC CAG CAG TAA TA
ChIP6–43.857.862-F GGG TCA TGA GCG CGG TAT TAC
ChIP6–43.858.070-R GGG CAG GTC GGA CAC CTT
Ctrl-43.870.329-F CTC ATC CAG GAG TTA TCG AGA ATA
Ctrl-43.870.406-R GAA ATG AAC CAC AGC ACT TCC
hACTgProm-H3K4-F ACC GGC AGA GAA ACG CGA
hACTgProm-H3K4-R CGG AAA GAT CGC CAT ATA TGG AC
hALD OA-H3K4-F TCC TGG CAA GAT AAG GAG TTG AC
hALD OA-H3K4-R ACA CAC GAT AGC CCT AGC AGT TC
ACT is actin and ALD OA aldolase A.
Table S3. Oligonucleotides for PCR assays (Continued)
